1 protocol(s) meet the specified criteria
Drug: Selinexor
Protocol No.TitleStatus
KCP-330-012STORMA Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Previously Treated with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an anti-CD38 Monoclonal Antibody (mAb) and Refractory to Prior Treatment with Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor and an anti-CD38 mAbOpen